


Transforming actigraphy in MND



Cory Holdom

Australian Institute for Bioengineering and Nanotechnology
University of Queensland



Motor neuron diseases



Motor neuron diseases



Motor neuron diseases



Capturing disease progression

Spirometry



Capturing disease progression

Spirometry



Self-report

Mary

ALSFRS Score = 40


Speech	4
Salivation	4
Swallowing	4
Handwriting	4
Cutting food	4
Dressing and hygiene	4
Turning in bed	3
Walking	3
Climbing stairs	2
Dyspnea (difficulty breathing)	2
Orthopnea (shortness of breath while lying down)	3
Breathing insufficiency	3

Capturing disease progression

Spirometry




Self-report


Mary

ALSFRS Score = 40

Speech	4
Salivation	4
Swallowing	4
Handwriting	4
Cutting food	4
Dressing and hygiene	4
Turning in bed	3
Walking	3
Climbing stairs	2
Dyspnea (difficulty breathing)	2
Orthopnea (shortness of breath while lying down)	3
Breathing insufficiency	3

Neurofilaments




Capturing disease progression

Spirometry




Self-report


Mary

ALSFRS Score = 40

Speech	4
Salivation	4
Swallowing	4
Handwriting	4
Cutting food	4
Dressing and hygiene	4
Turning in bed	3
Walking	3
Climbing stairs	2
Dyspnea (difficulty breathing)	2
Orthopnea (shortness of breath while lying down)	3
Breathing insufficiency	3

Neurofilaments





Physical activity




Wearable devices are ideal for passive, continuous biomarkers




Activity measures decline over time




Activity measures decline over time




Activity measures can be used to power trials



Activity measures can be used to power trials



Accelerometry captures a different aspect of MND to ALSFRS-R




We can measure disease progression through standard accelerometry

But can we make it better?

ADDS 2024

Transforming actigraphy in MND (Trac-MND)



Aim 1: Develop new patient-specific models for improved gait-analysis






Aim 2: Use redefined models to improve understanding of the variability in gait in patients with neurodegenerative disease.




Aim 3: Evaluate capacity of refined gait measures for use as remote measures of functional decline.



Patient movements on the treadmill



Examples of outputs from treadmill



Examples of outputs from treadmill



Next steps

- Validate treadmill-based step estimations
 - Lumbar, wrist, ankle
 - Case, control
- Identify specific, meaningful features of gait disruption for MND
 - Early, subclinical pathology
 - Fall risk assessments

Acknowledgements

Ngo & Steyn Groups



Dick Group



Dr Taylor
Dick



Dr James
Williamson



Dr Alexis
Brierty

ActiGraph



Dr Christine
Guo



Dr Rakesh
Pilkar



The Honda
Foundation



THE UNIVERSITY
OF QUEENSLAND
AUSTRALIA

Faculty of
Medicine



We acknowledge and thank all study participants, their families and friends for contributions to this research.



Questions?



ADDs 2024



**Thank You
for Your Time.**

c.holdom@uq.edu.au
@HoldomCory